Your browser is no longer supported. Please, upgrade your browser.
Settings
SLS SELLAS Life Sciences Group, Inc. daily Stock Chart
SLS [NASD]
SELLAS Life Sciences Group, Inc.
Index- P/E- EPS (ttm)-1.49 Insider Own2.04% Shs Outstand222.66M Perf Week-1.85%
Market Cap28.41M Forward P/E- EPS next Y-0.05 Insider Trans- Shs Float222.66M Perf Month-2.60%
Income-31.80M PEG- EPS next Q-0.02 Inst Own8.00% Short Float1.49% Perf Quarter-2.52%
Sales- P/S- EPS this Y69.80% Inst Trans- Short Ratio0.19 Perf Half Y-86.53%
Book/sh0.44 P/B0.29 EPS next Y64.30% ROA-133.50% Target Price1.75 Perf Year-93.68%
Cash/sh0.06 P/C2.22 EPS next 5Y- ROE-310.50% 52W Range0.10 - 2.46 Perf YTD-89.63%
Dividend- P/FCF- EPS past 5Y63.30% ROI- 52W High-94.81% Beta1.32
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin- 52W Low24.98% ATR0.01
Employees8 Current Ratio2.50 Sales Q/Q- Oper. Margin- RSI (14)47.76 Volatility5.44% 6.54%
OptionableNo Debt/Eq0.00 EPS Q/Q90.00% Profit Margin- Rel Volume0.34 Prev Close0.13
ShortableYes LT Debt/Eq0.00 EarningsNov 13 BMO Payout- Avg Volume17.66M Price0.13
Recom2.50 SMA203.04% SMA50-6.33% SMA200-81.67% Volume6,030,654 Change1.35%
Nov-01-18Initiated Oppenheimer Outperform
Apr-02-18Initiated H.C. Wainwright Buy $11
Mar-19-18Upgrade Maxim Group Hold → Buy $13
Aug-14-19 04:15PM  SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2019 Financial Results GlobeNewswire -8.01%
Aug-05-19 08:30AM  SELLAS Announces Completion of Enrollment in Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast GlobeNewswire
Jul-31-19 08:15AM  SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study GlobeNewswire -15.63%
Jun-22-19 10:10AM  Investors Who Bought SELLAS Life Sciences Group (NASDAQ:SLS) Shares A Year Ago Are Now Down 97% Simply Wall St.
Jun-18-19 04:33PM  SELLAS Life Sciences Announces Closing of $15 Million Public Offering GlobeNewswire
Jun-14-19 08:30AM  SELLAS Life Sciences Announces Pricing of $15 Million Public Offering GlobeNewswire -57.49%
Jun-03-19 08:30AM  SELLAS Announces Immune Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S (NPS) Plus Trastuzumab Presented at ASCO 2019 GlobeNewswire +11.76%
May-17-19 08:03AM  The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering Benzinga
May-15-19 04:30PM  SELLAS Life Sciences Provides Business Update and Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-04-19 08:30AM  SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM) GlobeNewswire
Mar-22-19 08:39AM  SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update GlobeNewswire -11.45%
Mar-04-19 08:30AM  SELLAS Life Sciences Announces Presentation of Final Data Analysis from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2019 ASCO-SITC Clinical Immuno-Oncology Meeting GlobeNewswire
Feb-26-19 10:49AM  Sellas Reviews Strategic Options To Fund Clinical Development Programs Benzinga
08:30AM  SELLAS Life Sciences Announces Review of Strategic Alternatives GlobeNewswire
Feb-12-19 08:45AM  SELLAS Life Sciences Provides Galinpepimut-S and Nelipepimut-S Program Update GlobeNewswire
Jan-31-19 08:30AM  SELLAS Life Sciences to Present at the 2019 BIO CEO & Investor Conference GlobeNewswire
Jan-08-19 08:30AM  SELLAS Life Sciences Provides Update on Late-Stage Immunotherapy Clinical Development Pipeline GlobeNewswire -7.69%
Dec-06-18 08:30AM  SELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data from Phase 2b Study of Nelipepimut-S Plus Trastuzumab  at the 2018 San Antonio Breast Cancer Symposium GlobeNewswire -5.91%
Nov-30-18 08:30AM  SELLAS to Present Further Correlative Data from Phase 2b Trial of NeuVax + Herceptin® at the 2018 San Antonio Breast Cancer Symposium GlobeNewswire +9.14%
Nov-28-18 08:30AM  SELLAS Life Sciences Announces Expedited Development Path for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Following Feedback from FDA GlobeNewswire
Nov-26-18 08:30AM  SELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study of Nelipepimut-S Plus Trastuzumab in High-risk, High-expression HER2 Breast Cancer Patients GlobeNewswire
Nov-15-18 07:30AM  SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2018 Financial Results GlobeNewswire -13.85%
Nov-12-18 07:00AM  SELLAS Life Sciences Settles Lawsuit and Prepares to Advance Galinpepimut-S, Analysts Review ACCESSWIRE +12.50%
Nov-09-18 10:00AM  Health Care Stocks Making Moves On Friday; Premier Health Group, Inc. (PHGRF) (PHGI), Sellas Life Sciences, Teladoc ACCESSWIRE
08:55AM  SELLAS Life Sciences Announces Additional Data Showing Consistent Clinical Effect Across HLA Allele Subgroups in Triple Negative Breast Cancer (TNBC) Patients Treated with Nelipepimut-S Plus Trastuzumab Presented at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting GlobeNewswire
08:30AM  SELLAS Life Sciences Announces Settlement of Counterclaims Against JGB (Cayman) Newton, Ltd. for $6.6 Million Payment by JGB GlobeNewswire
Nov-08-18 08:45AM  SELLAS Life Sciences to Provide Third Quarter 2018 Financial Results and Corporate Update on November 15, 2018 GlobeNewswire +7.47%
Nov-06-18 09:30AM  Big Biotech May Be After These Technologies ACCESSWIRE
Nov-02-18 08:00AM  Todays Research Reports on Stocks to Watch: Teva Pharmaceutical and SELLAS Life Sciences ACCESSWIRE +7.83%
Nov-01-18 10:05AM  3 Biotechnology & Healthcare Stocks To Watch On Thursday ACCESSWIRE +36.07%
Oct-22-18 07:00AM  SELLAS Life Sciences Announces Positive Final Data in Triple Negative Breast Cancer Patients from Phase 2b Clinical Trial of Nelipepimut-S (NeuVax) in Combination with Trastuzumab (Herceptin®) Presented at the European Society for Medical Oncology (ESMO) 2018 Annual Meeting GlobeNewswire -14.10%
Oct-19-18 08:05AM  Data Safety Monitoring Board Confirms Triple Negative Breast Cancer as the Target Patient Population for Development of NeuVax (nelipepimut-S) in Combination with Trastuzumab (Herceptin®) in HER2 1+/2+ Breast Cancer Patients Following Final Analysis of Phase 2B Trial GlobeNewswire -13.33%
Oct-16-18 01:12PM  The SELLAS Life Sciences Group Inc (NASDAQ:SLS) Ownership Structure Could Be Important Simply Wall St. +20.00%
Oct-15-18 08:30AM  SELLAS to Host Conference Call Following Oral Presentation of Phase 2b Results of NeuVax + Herceptin® to Prevent Breast Cancer Recurrence at the European Society for Medical Oncology (ESMO) 2018 Annual Meeting GlobeNewswire +12.00%
Oct-02-18 04:01PM  SELLAS to Present Data from Phase 2b Trial of NeuVax + Herceptin® at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire +39.83%
Sep-24-18 04:30PM  SELLAS Life Sciences to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire +8.33%
Sep-13-18 08:30AM  SELLAS Receives Orphan Medicinal Product Designation Approval by the Committee for Orphan Medicinal Products of the European Medicines Agency for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma GlobeNewswire
Aug-16-18 09:37AM  The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait Benzinga
Aug-15-18 08:00AM  SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2018 Financial Results GlobeNewswire -12.94%
Jul-20-18 11:05AM  Sellas Life Sciences' Cancer Vaccine Candidate Wins Fast Track Designation In Multiple Myeloma Benzinga
08:30AM  SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma GlobeNewswire
Jul-16-18 11:23AM  SELLAS Life Sciences Announces Closing of $24.2 Million Public Offering GlobeNewswire
Jul-12-18 08:45AM  SELLAS Life Sciences Announces Pricing of Upsized $24.2 Million Public Offering GlobeNewswire -30.60%
07:20AM  Breakfast Technical Briefing on Tetraphase Pharma and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-26-18 07:46AM  SELLAS Life Sciences Announces Proposed Public Offering of Common Stock GlobeNewswire -18.22%
Jun-07-18 07:35AM  Today's Free Research Reports Coverage on Seattle Genetics and Three More Biotech Stocks ACCESSWIRE
Jun-04-18 08:45AM  SELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S (GPS) in Combination with Nivolumab to Treat Wilms Tumor 1 Positive (WT1+) Ovarian Cancer Patients at ASCO 2018 GlobeNewswire
Jun-01-18 08:45AM  SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients GlobeNewswire +6.76%
May-17-18 08:45AM  SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-09-18 04:30PM  SELLAS Life Sciences Receives FDA Orphan Drug Designation for Galinpepimut-S (GPS) for Treatment of Multiple Myeloma (MM) GlobeNewswire
May-02-18 08:45AM  SELLAS Life Sciences Completes Second Tranche of $10,700,000 Private Placement GlobeNewswire
Apr-20-18 08:45AM  SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer GlobeNewswire -5.94%
Apr-16-18 09:00AM  SELLAS Life Sciences Reports Corporate Highlights, Advancements for its Cancer Immunotherapy Pipeline and 2017 Financial Results GlobeNewswire
Apr-05-18 02:43PM  MARKETS: Stocks bust higher, Facebook fake out, Boeing bump, financials turn green Yahoo Finance Video
Apr-02-18 12:18PM  What's NeuVax? Wainwright Says Sellas' Cancer Vaccine Candidate Makes It A Buy Benzinga +150.72%
08:40AM  SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax (nelipepimut-S) Clinical Trial in Combination with Herceptin® in HER2 1+/2+ Breast Cancer Patients GlobeNewswire
Mar-29-18 01:59PM  Loss-Making SELLAS Life Sciences Group Inc (NASDAQ:SLS) Expected To Breakeven Simply Wall St.
Mar-21-18 08:45AM  SELLAS Life Sciences Announces Appointment of Barbara A. Wood as Executive Vice President, General Counsel and Corporate Secretary GlobeNewswire +6.20%
Mar-19-18 08:45AM  SELLAS Life Sciences Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting GlobeNewswire
Mar-15-18 08:45AM  SELLAS Life Sciences Group Announces Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering Composition of Matter for WT-1 Peptides GlobeNewswire
Mar-13-18 04:15PM  SELLAS Life Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-07-18 09:00AM  SELLAS Life Sciences Announces $10,700,000 Private Placement GlobeNewswire -15.33%
Mar-05-18 04:15PM  SELLAS Life Sciences to Present at the 30th Annual ROTH Conference GlobeNewswire
Feb-27-18 08:45AM  Data From SELLAS Life Sciences Positive Phase 2 Acute Myeloid Leukemia Study Published in American Society of Hematologys Journal, Blood Advances GlobeNewswire
Feb-06-18 08:30AM  SELLAS Life Sciences to Present at Two Upcoming February Investor Conferences GlobeNewswire
Feb-01-18 04:01PM  Women In Bio Announces Jane Wasman Appointed Chair of Sellas Life Sciences Board of Directors GlobeNewswire
Jan-24-18 08:55AM  SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting GlobeNewswire
Jan-23-18 02:03PM  Whats Installed For SELLAS Life Sciences Group Inc (NASDAQ:SLS)? Simply Wall St.
Jan-06-18 03:10PM  What You Must Know About SELLAS Life Sciences Group Incs (NASDAQ:SLS) Major Investors Simply Wall St.
Dec-29-17 04:46PM  SELLAS Life Sciences Group Successfully Completes Business Combination with Galena Biopharma GlobeNewswire -5.11%
SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.